Flerie AB successfully completes its merger with Toleranzia AB, enhancing its position in the Life Science sector.

Information on the Target

Flerie AB (publ) is an active and long-term investor in the Life Science sector, boasting a diverse portfolio of innovative companies with groundbreaking technologies. The company focuses on global investments in product development and commercial growth, aiming primarily at hard-to-reach private companies. Flerie's active ownership model, extensive networks, and resources are leveraged to support and accelerate the development of its portfolio companies' projects, ultimately creating value for its shareholders. Flerie AB's shares are publicly traded on Nasdaq Stockholm under the ticker FLERIE.

Toleranzia AB (publ) is a biotechnology company specializing in the development of innovative treatments for autoimmune diseases. The company has made significant advancements in the field and serves as a strong addition to Flerie's existing portfolio. The completion of the merger between Flerie and Toleranzia facilitates the consolidation of Toleranzia's assets and operations under Flerie’s corporate structure.

Industry Overview in Sweden

The Life Science industry in Sweden is robust and characterized by a strong emphasis on innovation and research. Sweden is home to numerous life science companies that specialize in pharmaceuticals, biotechnology, and medic